NOVEL CHEMOTHERAPY FOR LEUKAEMIA INDUCING DIFFERENTIATION IN BLOCKED PROGENITORS (K562)

Nasef Malak; Aziz Athar

doi:10.59743/jbs.v37i1.249

المؤلفون

Nasef Malak Alasmarya Islamic University, Libya
Aziz Athar Salford University,UK

DOI:

https://doi.org/10.59743/jbs.v37i1.249

الكلمات المفتاحية:

Chemotherapy، cancer، erythroleukemic، globin genes

الملخص

Chemotherapy is a major branch of treatment used for cancer patients especially leukaemia, studying the mechanism of cancer and the process that follow and effects can help the scientists to put targets in their treatment and finding a novel therapeutics can be more effects and reduce the symptoms that go along with cancer and side effects of chemotherapy , one of these symptoms in leukaemia patients is anaemia, In this experiment four different drugs with four different concentration working as chemical inhibitors were used to treat erythroleukemic cell line (K562) these cells has the potential to be differentiate to red blood cells , platelets and certain types of white blood cells, RNA was extracted from the samples and gene expression test of globin genes was tested, globin genes test represents an expression of HBA gene at low concentration so these results give a promising chemotherapy and it is drug A(flavone) at low concentration especially at the concentration of 1µM so as a result drug A has the ability to open the blocked progenitors and induce the survival cells to be differentiate and be committed cells to produce a mature red blood cells.

المراجع

L.C.Andersson , K. Nillsson , and Gahmberg C.G. “A human erythroleukemic K562 cell line,”. International Journal of cancer ., vol . 23,no. 2 , pp. 143–147, 1979.

G.B. Adam, and D.T. Scadden, “ The hematopoirtic stem cell in its place,”. Nat Immunol., vol. 7, pp. 333–337, 2006.

Cancer Research UK (2014). “Cancer growth blockers, ”.www.cancerresearch.org.uk ,Accessed on: September .16, 2015.

J.E. Dancey , P.L., Bedard , N. Onetto, and T.J. Hudson. “The genetic basis for cancer treatment decisions,”. Cell .,vol. 148,pp. 409–420, 2012.

C.M. Fordis , N.P. Anagnou, A.Dean, A.W Nienhuis,and A.N. Schechter, “Abeta -globin gene ,inactive in theK562 leukemic cell, function normally in a heterologous expression system,” .Proc Natl Acad Sci USA, vol. 81,pp.4485–4489, 1984.

C. Friend, W. Scher, J. G. Holland, and T. Sato, “Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide,”. Proc. Natl. Acad. Sci. USA , vol. 68, pp.378–382, 1971.

S.K. Grant , “Therapeutic protein kinase inhibitors,”. Cell Mol. Life Sci. , vol.66, no. 77, pp.1163–1177, 2009.

R. Hesketh, “Introduction to cancer biology,” .Cambridge University Press , Cambridge , 2013.

Y. Koiso, O. Nakajim, D. Matsumura, Y. Fujimoto , and Y.Hashimoto , “Chemical control of cell differentiation of human myeloleukemia K562 cell line,”. Yakugaku Zasshi , vol.120, pp.104–112, 2000.

A. H. Lund, and M.V. Lohuizen , “Epigenetic and cancer,”. Genes and Development, vol.18, pp. 2315- 2335,2004.

D., MacGrogan , N. Kalakonda , S. Alvarez , J.M. Scandura , P. Boccuni , B. Johansson , and S.D. Nimer , “Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells ,”.Genes Chromosomes and Cancer , vol.41,no.3,pp.203-213,2004.

P. A. Marks, and R. A. Rifkind, “Erythroleukemic differentiation,”.Annu. Rev. Biochem, vol. 47, pp. 419–448, 1978.

O., Nakajima, S. Iwasaki, and Y. Hashimoto, “Hemin-induced erythroid differentiation of human myeloleukemia K562 cell line and its modification by bioresponse modifiers,” .Cell Mol. Biol., vol.43, pp. 115–134, 1997.

L.A. Saddic , L.E.West , A. Aslanian , J.R. Yates , S.M. Rubin , O. Gozani , and J. Sage , “ Methylation of the retinoblastoma tumor suppressor by SMYD2,” . J. Biol. Chem, vol. 285,no. 48,pp.37733–37740,2009.

J.Shendur , and H. Ji , “Next-generation DNA sequencing,” . Nature Biotechnology, vol. 26, pp.1135-1145, 2008.

A. S. Tsiftsoglou, I. S. Pappas, and I. S. Vizirianakis, “Mechanisms involved in the induced differentiation of leukemia cells,”. Pharmacol. Ther. Vol.100, pp. 257–290, 2003.

A.S. Tsiftsoglou, I.S. Vizirianakis, and J. Strouboulis, “Erythropoiesis : model system , molecular regulators, and developmental programs,”. IUBMB Life,vol. 61,no.8, pp.800–830, 2009.

A. S. Tsiftsoglou, A. I. Tsamadou, and L. C. Papadopoulou, “Heme as key regulator of major mammalian cellular functions: molecular,cellular, and pharmacological aspects,”. Pharmacol. Ther.vol.111, pp.327–345, 2006.

L.E. West , S. Roy , K. Lachmi-Weiner , R. Hayashi , X. Shi , E. Appella , T.G. Kutateladze , and O. Gozani , “The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression,”. The Journal of Biological Chemistry, vol.258, no.48, pp. 37725–37732, 2010.

I. L. Weissman, “Stem cells: units of development, units of regeneration, and units in evolution,”. Cell, vol. 100,pp. 157–168, 2000.